Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials
James N. George(University of Oklahoma), Martin R. Schipperus(Rijnland Ziekenhuis), Lawrence Rice(Methodist Hospital), Robert L. Redner(UPMC Hillman Cancer Center), Susan D. Mathias(Health Outcomes Solutions (United States)), Matthew Guo(Eisai (United States)), Roger M. Lyons(Hematology Oncology Associates), David H. Henry(Pennsylvania Hospital), Ronald S. Go(Mayo Clinic)
Cited by 146
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697